The renin-angiotensin system and treatment of heart failure

作者: Fetnat M. Fouad-Tarazi , F.Merlin Bumpus , Mahesh Khosla , Bernadine Healy

DOI: 10.1016/0002-9343(88)90209-4

关键词:

摘要: From the Heart and Hypertension Department, Research Institute of Cleveland Clinic Foundation, Cleveland, Ohio. Requests for reprints should be addressed to Dr. Fetnat M. Fouad-Taraii, 9500 Euclid Avenue, Ohio 44106. It has been years since converting enzyme inhibitors were introduced treatment congestive heart failure. Their effectiveness demonstrated in multiple reports that have shown improvement hemodynamic indexes as well clinical symptoms quality life [l-IO]. Moreover, this generally lasted months or years. Our experience respect is summarized Table I. We studied 14 patients with failure ischemic cardiomyopathic etiology, before after captopril therapy, obtained data at regular intervals over one year. These studies showed cardiac output stroke volume increased significantly association normalization pulmonary mean transit time, reduction plasma aldosterone, some both catecholamine levels rate. effects occurred within week sustained. Changes ejection fraction, however, minimal compared significant time (Figure 1) probably because fraction depends on left ventricular geometry addition loading conditions heart. Along these findings, severity (NYHA class) its other manifestations described treated by Dzau et al [7], Levine [8], others. Goldstein Pitt [l l] also that, placebo digoxin, resulted improved exercise duration, a 45 percent premature beats, frequency hospitalization. The mechanism which maintain still not understood. Several possibilities include: (1) persistent beneficial inhibition o’n afterload preload; (2) suppression aldosterone; (3) interference angiotensin II renal tubules; (4) direct effect accumulated I v21. Compared vasodilators, found more effective improving effort tolerance marked blood pressure increase [13]. findings indicated changes induced are only factors mediating long-term control during therapy. therapy was observed vasodilators but did develop when used similar suggesting additional considered. For example, humoral pa-

参考文章(27)
K M Baker, M C Khosla, Cardiac and vascular actions of decapeptide angiotensin analogs. Journal of Pharmacology and Experimental Therapeutics. ,vol. 239, pp. 790- 796 ,(1986)
A. Ortiz, M. Quevedo, M. Lazo, A. Illanes, J. Pérez-Olea, INFLUENCE OF ANGIOTENSIN ON THE EFFECTS OF TYRAMINE UPON THE CONTRACTILE FORCE OF ISOLATED RABBIT ATRIA Journal of Pharmacology and Experimental Therapeutics. ,vol. 158, pp. 487- 493 ,(1967)
GustaveA. Turini, HansR. Brunner, Milan Gribic, Bernard Waeber, Haralambos Gavras, IMPROVEMENT OF CHRONIC CONGESTIVE HEART-FAILURE BY ORAL CAPTOPRIL The Lancet. ,vol. 313, pp. 1213- 1215 ,(1979) , 10.1016/S0140-6736(79)91897-X
Victor J. Dzau, Wilson S. Colucci, Gordon H. Williams, Gregory Curfman, Leonard Meggs, Norman K. Hollenberg, Sustained Effectiveness of Converting-Enzyme Inhibition in Patients with Severe Congestive Heart Failure New England Journal of Medicine. ,vol. 302, pp. 1373- 1379 ,(1980) , 10.1056/NEJM198006193022501
S K Mujais, F M Fouad, S C Textor, R C Tarazi, E L Bravo, N Hart, R W Gifford, Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure Heart. ,vol. 52, pp. 63- 71 ,(1984) , 10.1136/HRT.52.1.63
Najam A. Awan, Mark K. Evenson, Kathleen E. Needham, Aung Win, Dean T. Mason, Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure. American Heart Journal. ,vol. 101, pp. 22- 31 ,(1981) , 10.1016/0002-8703(81)90379-3
George J. Trachte, John A. Ackerly, Michael J. Peach, Inotropic cardiac and vascular actions of [Ala7]angiotensin analogs Journal of Cardiovascular Pharmacology. ,vol. 3, pp. 838- 846 ,(1981) , 10.1097/00005344-198107000-00017
Robert C. Tarazi, Fetnat M. Fouad, Joanne K. Ceimo, Emmanuel L. Bravo, Renin, aldosterone and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure. American Journal of Cardiology. ,vol. 44, pp. 1013- 1018 ,(1979) , 10.1016/0002-9149(79)90237-6
Pieter A. degraeff, Cees D.J. delangen, Wiek H. van Gilst, Klaas Bel, Egbert Scholtens, J.Herre Kingma, Harry Wesseling, Protective Effects of Captopril against Ischemia/Reperfusion-Induced Ventricular Arrhythmias in Vitro and in Vivo The American Journal of Medicine. ,vol. 84, pp. 67- 74 ,(1988) , 10.1016/0002-9343(88)90207-0
R.B. Cross, C. Dallemagne, E. Beswick, M.C. Khosla, F.M. Bumpus, A cardiac specific analog of angiotensin I potentiated by converting enzyme inhibition Life Sciences. ,vol. 36, pp. 613- 618 ,(1985) , 10.1016/0024-3205(85)90164-X